Diadema Partners LP Acquires New Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Diadema Partners LP purchased a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 49,478 shares of the company's stock, valued at approximately $948,000. Diadema Partners LP owned approximately 0.06% of Viridian Therapeutics as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Loomis Sayles & Co. L P purchased a new stake in shares of Viridian Therapeutics during the 4th quarter worth $26,845,000. FMR LLC lifted its stake in Viridian Therapeutics by 6.2% during the fourth quarter. FMR LLC now owns 11,881,912 shares of the company's stock worth $227,776,000 after purchasing an additional 698,434 shares during the last quarter. Victory Capital Management Inc. acquired a new position in Viridian Therapeutics in the fourth quarter valued at approximately $7,868,000. Lord Abbett & CO. LLC purchased a new position in Viridian Therapeutics in the third quarter valued at approximately $8,917,000. Finally, Raymond James Financial Inc. acquired a new stake in Viridian Therapeutics during the fourth quarter worth approximately $6,015,000.

Viridian Therapeutics Stock Performance

Shares of NASDAQ VRDN traded down $0.06 during mid-day trading on Friday, hitting $13.50. 524,676 shares of the company were exchanged, compared to its average volume of 1,203,124. The stock has a 50 day simple moving average of $14.24 and a 200-day simple moving average of $18.24. Viridian Therapeutics, Inc. has a 1-year low of $9.90 and a 1-year high of $27.20. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -3.13 and a beta of 0.81.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.24. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. On average, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on VRDN. Needham & Company LLC restated a "buy" rating and issued a $38.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 7th. HC Wainwright reissued a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a report on Wednesday. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Viridian Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.